Kaken Pharmaceutial
4521.TPharmaceutical
Filed as KAKEN PHARMACEUTICAL CO., LTD. (2022-06–2026-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥72.3bn | ¥93.9bn | ¥72.0bn | ¥72.9bn | ¥75.9bn | ¥73.9bn |
| Operating income | −¥694m | ¥22.5bn | ¥9.8bn | ¥8.4bn | ¥17.4bn | ¥17.7bn |
| Ordinary income | −¥112m | ¥22.8bn | ¥10.2bn | ¥8.9bn | ¥17.9bn | ¥18.2bn |
| Total assets | ¥172.1bn | ¥189.5bn | ¥168.9bn | ¥163.7bn | ¥161.8bn | ¥162.3bn |
| Net assets / equity | ¥147.2bn | ¥153.5bn | ¥143.3bn | ¥136.6bn | ¥136.6bn | ¥135.0bn |
| EPS (basic) | ¥51.84 | ¥431.06 | ¥224.79 | ¥180.07 | ¥260.61 | ¥346.63 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Medicine | ¥74.3bn | −¥2.3bn |
| Real Estate | ¥2.5bn | ¥1.4bn |
| Adjustments & eliminations | — | — |
| Total | ¥76.9bn | −¥899m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.